Search research articles
Contact Us
Filters
Showing results (461-470 of 475) with videos related to
Page
of 48
Sort By:
Circulation
|
December 6, 2021
Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination
Dongngan T Truong, Audrey Dionne, Juan Carlos Muniz, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Neratinib in Early Breast Cancer
John W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell
|
June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M Wolf, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
Hope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
JACC. Advances
|
March 27, 2025
ICU Admission Prediction for Patients With Kawasaki Disease or MIS-C Using Machine Learning
JiWon Woo, Rebecca Mosier, Rishima Mukherjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery
Kathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
NPJ Breast Cancer
|
December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Julie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Nature Medicine
|
September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Katia Khoury, Jane L Meisel, Christina Yau, et al.
NPJ Breast Cancer
|
October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Douglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Page
of 48
Search research articles
Search
Showing results (461-470 of 475) with videos related to
Sort By:
Page
of 48
Circulation
|
December 6, 2021
Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination
Dongngan T Truong, Audrey Dionne, Juan Carlos Muniz, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Neratinib in Early Breast Cancer
John W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell
|
June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M Wolf, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
Hope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
JACC. Advances
|
March 27, 2025
ICU Admission Prediction for Patients With Kawasaki Disease or MIS-C Using Machine Learning
JiWon Woo, Rebecca Mosier, Rishima Mukherjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery
Kathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
NPJ Breast Cancer
|
December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Julie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Nature Medicine
|
September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Katia Khoury, Jane L Meisel, Christina Yau, et al.
NPJ Breast Cancer
|
October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Douglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Page
of 48